JPMorgan downgraded Intellia Therapeutics (NTLA) to Underweight from Neutral with a price target of $5, down from $12. The firm left the company’s earnings call with more questions than answers. “There are serious hurdles the company needs to address in the coming months,” the analyst tells investors in a research note. JPMorgan says assuming understanding the cause behind the liver toxicity events will not be easy to overcome and will take time.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics: Buy Rating Affirmed Amid HAE Program Optimism Despite ATTR Setback
- Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings
- Intellia Therapeutics: Buy Rating Backed by MAGNITUDE Trial Resumption and Promising Data Releases
- Cathie Wood Cuts Stake in Palantir Stock (PLTR) Ahead of Q3, Loads Up on Bullish (BLSH) and Intellia (NTLA)
- DoorDash, Microsoft, Intellia, Upwork, Qorvo: Trending by Analysts